Analysts/Institutional Investor Meet/Con. Call Updates30 Oct 2026 · 17:29
Cipla Limited has informed the Exchange about Transcript
Markets / Nifty 50 / Healthcare
Price
Daily closing prices, adjusted for bonuses and splits
Returns against the Nifty 50
| Return | 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|
| CIPLA | +2.7% | +5.0% | −3.9% | +2.8% | −6.7% | +16.2% | +53.9% |
| Nifty 50 | +5.6% | +6.2% | −2.7% | −1.5% | −6.4% | +24.6% | +33.7% |
Price returns, without dividends. Source: NSE end-of-day data.
Check-up
Where CIPLA sits against the Nifty 50 and its industry. Facts, not advice.
Price return
−6.74%
Over 1 year. The Nifty 50 returned −6.40%, so CIPLA trailed it by 0.3 percentage points.
Valuation (PE)
39.1
Price is 39.1 times the last four quarters' earnings per share, higher than the Nifty 50's PE of 19.8 and the 4 industry peers' median of 48.1.
Growth
−2.4%
Revenue in Q2 FY27 compared with the same quarter a year earlier. Net profit changed −35.1%.
Profitability (ROE)
8.2%
Profit over the last four quarters as a share of shareholders' equity. Net margin is 10.3%.
Debt
0.01×
Borrowings are 0.01 times shareholders' equity (latest balance sheet, 30 Sep 2026).
Volatility
1.45×
Daily price moves over the last year were 1.45 times as large as the Nifty 50's (annualised volatility 20.1%).
What the latest numbers show
Calculated by stockER from the company's filings and NSE data.
Positives 2
- Operating cash flow of ₹3,940 crCash generated by the business in the year to 31 Mar 2026.
- Mutual fund holding up 0.55 points in a year20.78% on 30 Sep 2026, from 20.23%.
Watch points 5
- Revenue down 2.4% from a year ago₹7,404 cr in Q2 FY27, against ₹7,589 cr in Q2 FY26.
- Net profit down 37.1% from a year ago₹852 cr in Q2 FY27, against ₹1,353 cr in Q2 FY26.
- Net margin narrowed to 11.5%From 17.8% in Q2 FY26.
- Borrowings rose 183.7% in a year₹267 cr on 30 Sep 2026, against ₹94 cr a year earlier.
- Foreign institutional holding down 4.30 points in a year20.25% on 30 Sep 2026, from 24.55%.
Financials
Consolidated results as filed with NSE. ₹ crore unless stated.
Revenue
Net profit
EPS (₹)
| ₹ crore | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 7,073 | 6,730 | 6,957 | 7,589 | 7,074 | 6,541 | 7,119 | 7,404 |
| Other income | 222 | 289 | 259 | 269 | 206 | 148 | 211 | 151 |
| Total expenses | 5,378 | 5,515 | 5,446 | 6,005 | 6,112 | 5,982 | 6,248 | 6,378 |
| EBITDA | 2,211 | 1,827 | 2,037 | 2,164 | 1,185 | 1,103 | 1,403 | 1,539 |
| Depreciation | 280 | 309 | 253 | 297 | 278 | 383 | 304 | 345 |
| Finance cost | 15 | 14 | 14 | 13 | 14 | 13 | 17 | 17 |
| PBIT | 1,931 | 1,518 | 1,784 | 1,867 | 907 | 720 | 1,099 | 1,194 |
| Profit before tax | 1,916 | 1,504 | 1,770 | 1,854 | 893 | 707 | 1,082 | 1,177 |
| Tax | 332 | 279 | 478 | 500 | 219 | 157 | 295 | 321 |
| Net profit | 1,575 | 1,214 | 1,292 | 1,353 | 674 | 543 | 786 | 852 |
| EPS (₹) | 19.45 | 15.13 | 16.07 | 16.73 | 8.37 | 6.87 | 9.77 | 10.86 |
| ₹ crore | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue from operations | 25,774 | 27,548 | 28,163 |
| Other income | 747 | 862 | 882 |
| Total expenses | 20,624 | 21,589 | 23,545 |
| EBITDA | 6,843 | 7,990 | 6,489 |
| Depreciation | 1,051 | 1,107 | 1,211 |
| Finance cost | 90 | 62 | 54 |
| PBIT | 5,792 | 6,883 | 5,278 |
| Profit before tax | 5,702 | 6,821 | 5,224 |
| Tax | 1,547 | 1,530 | 1,354 |
| Net profit | 4,154 | 5,269 | 3,862 |
| ₹ crore | MAR 2024 | SEP 2024 | MAR 2025 | SEP 2025 | MAR 2026 | SEP 2026 |
|---|---|---|---|---|---|---|
| Total assets | 32,718 | 34,655 | 37,387 | 40,164 | 42,496 | 43,434 |
| Current assets | 19,392 | 20,906 | 23,249 | 24,918 | 24,146 | 25,061 |
| Inventories | 5,238 | 5,573 | 5,642 | 6,160 | 6,597 | 6,778 |
| Cash and equivalents | 640 | 798 | 589 | 762 | 1,018 | 1,659 |
| Total liabilities | 5,915 | 6,200 | 6,098 | 7,139 | 7,976 | 7,912 |
| Current liabilities | 5,246 | 5,455 | 5,484 | 6,297 | 7,014 | 6,977 |
| Borrowings | 247 | 162 | 92 | 94 | 258 | 267 |
| Shareholders' equity | 26,802 | 28,456 | 31,289 | 33,025 | 34,520 | 35,522 |
| Equity attributable to owners | 26,706 | 28,362 | 31,193 | 32,919 | 34,432 | 35,396 |
Balance sheets are filed every half year (September and March).
| ₹ crore | 6M to SEP 2022 | 12M to MAR 2025 | 6M to SEP 2025 | 12M to MAR 2026 | 6M to SEP 2026 |
|---|---|---|---|---|---|
| From operations | 1,134 | 5,005 | 1,345 | 3,940 | 1,219 |
| From investing | −620 | −3,691 | 159 | −2,326 | 446 |
| From financing | −517 | −1,293 | −1,318 | −1,234 | −1,055 |
| Capital expenditure | 392 | 1,162 | 665 | 1,599 | 917 |
| Free cash flow | 741 | 3,843 | 680 | 2,341 | 302 |
Cash flow statements are filed every half year; figures are for the period shown.
EBITDA here is profit before tax plus finance cost and depreciation. Annual figures add up the four quarters of each financial year. Source: company filings on NSE (XBRL).
Peers
Healthcare companies in the Nifty 50.
| Company | Price | Market cap | PE | PB | ROE | Div. yield | 1Y return |
|---|---|---|---|---|---|---|---|
| Cipla Ltd.CIPLA | ₹1,402.00 | ₹1.13 lakh cr | 39.1 | 3.20 | 8.2% | 0.93% | −6.7% |
| Sun Pharmaceutical Industries Ltd.SUNPHARMA | ₹1,773.40 | ₹4.25 lakh cr | 38.8 | 4.77 | 12.3% | 0.90% | +4.9% |
| Apollo Hospitals Enterprise Ltd.APOLLOHOSP | ₹8,599.50 | ₹1.24 lakh cr | 55.1 | 11.66 | 21.1% | 0.23% | +10.1% |
| Dr. Reddy's Laboratories Ltd.DRREDDY | ₹1,374.00 | ₹1.15 lakh cr | 41.0 | 2.96 | 7.2% | 0.58% | +14.5% |
| Max Healthcare Institute Ltd.MAXHEALTH | ₹927.15 | ₹90,240 cr | 65.4 | 7.96 | 12.2% | 0.22% | −18.6% |
Price comparison
Change in price from the start of the period
CIPLANifty 50SUNPHARMAAPOLLOHOSP
Events
Dividends, bonuses and splits from NSE's corporate actions.
Dividend paid in 5 of the last 5 calendar years (2022–2026)Over the last 12 months: ₹13.00 per share (adjusted for bonuses and splits), a yield of 0.93% at today's price.
Past dividends
Dividend
Dividend - Rs 13 Per SharePer share
₹13.00Ex-date
5 Jun 2026
Dividend - Rs 13 Per SharePer share
₹13.00Ex-date
5 Jun 2026
Special dividend
Dividend - Rs 13 Per Share/Special Dividend - Rs 3 Per SharePer share
₹16.00Ex-date
27 Jun 2025
Dividend - Rs 13 Per Share/Special Dividend - Rs 3 Per SharePer share
₹16.00Ex-date
27 Jun 2025
Dividend
Dividend - Rs 13 Per SharePer share
₹13.00Ex-date
2 Aug 2024
Dividend - Rs 13 Per SharePer share
₹13.00Ex-date
2 Aug 2024
Dividend
Dividend - Rs 8.50 Per SharePer share
₹8.50Ex-date
21 Jul 2023
Dividend - Rs 8.50 Per SharePer share
₹8.50Ex-date
21 Jul 2023
Dividend
Dividend - Rs 5 Per SharePer share
₹5.00Ex-date
8 Aug 2022
Dividend - Rs 5 Per SharePer share
₹5.00Ex-date
8 Aug 2022
Dividend
Annual General Meeting/Dividend - Rs 5 Per SharePer share
₹5.00Ex-date
9 Aug 2021
Annual General Meeting/Dividend - Rs 5 Per SharePer share
₹5.00Ex-date
9 Aug 2021
Interim dividend
Interim Dividend - Rs 3 Per Share Special Dividend - Re 1 Per SharePer share
₹4.00Ex-date
19 Mar 2020
Interim Dividend - Rs 3 Per Share Special Dividend - Re 1 Per SharePer share
₹4.00Ex-date
19 Mar 2020
Dividend
Annual General Meeting/Dividend - Rs 3 Per SharePer share
₹3.00Ex-date
31 Jul 2019
Annual General Meeting/Dividend - Rs 3 Per SharePer share
₹3.00Ex-date
31 Jul 2019
Bonuses, splits and other actions
Annual General MeetingEx-date
11 Aug 2020
11 Aug 2020
Agm/Div-Rs.2/- Per ShareEx-date
10 Aug 2009
10 Aug 2009
Filings and updates
The company's own announcements to NSE: results, dividends, presentations and board decisions.
Annual report 2025–26Open (PDF / ZIP)
Annual report 2024–25Open (PDF / ZIP)
Annual report 2023–24Open (PDF / ZIP)
Annual report 2022–23Open (PDF / ZIP)
Annual report 2021–22Open (PDF / ZIP)
ESOP/ESOS/ESPS29 Oct 2026 · 20:29
Cipla Limited has informed the Exchange regarding Allotment of 17453 Shares.
Copy of Newspaper Publication28 Oct 2026 · 15:52
Please find enclosed newspaper intimation for unaudited financial results for the quarter and half year ended 30th September, 2026.
Analysts/Institutional Investor Meet/Con. Call Updates27 Oct 2026 · 18:45
Cipla Limited has informed the Exchange about Link of Recording
Outcome of Board Meeting27 Oct 2026 · 13:45
Cipla Limited has informed the Exchange regarding Outcome of Board Meeting held on October 27, 2026.
Appointment27 Oct 2026 · 13:43
Cipla Limited has informed the Exchange regarding Appointment of Ms Rashmi Joshi as Independent Director of the company w.e.f. October 27, 2026.
Investor Presentation27 Oct 2026 · 13:38
Cipla Limited has informed the Exchange about Investor Presentation
Press Release27 Oct 2026 · 13:33
Cipla Limited has informed the Exchange regarding a press release dated October 27, 2026, titled "Q2FY27 Financial Results".
Outcome of Board Meeting27 Oct 2026 · 13:31
Cipla Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Analysts/Institutional Investor Meet/Con. Call Updates13 Oct 2026 · 18:54
Cipla Limited has informed the Exchange about Schedule of meet
ESOP/ESOS/ESPS24 Sep 2026 · 19:03
Cipla Limited has informed the Exchange regarding Allotment of 12168 Shares.
Press Release3 Sep 2026 · 20:13
Cipla Limited has informed the Exchange regarding a press release dated September 03, 2026, titled "Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US".
Frequently asked questions
What is the share price of Cipla Ltd. (CIPLA)?
CIPLA closed at ₹1,402.00 on NSE on 4 Nov 2026, +0.37% on the day. stockER shows end-of-day prices, updated after the market closes.
What is the market cap of CIPLA?
₹1.13 lakh cr, based on 80.79 crore shares and the latest closing price. That makes it #47 by size in the Nifty 50.
What are the PE and PB ratios of CIPLA?
PE 39.10 on earnings per share of ₹35.86 over the last four quarters; PB 3.20 on the latest reported equity.
What is the 52-week high and low of CIPLA?
High ₹1,593.30 on 30 Oct 2025, low ₹1,165.70 on 2 Apr 2026 (adjusted for bonuses and splits).
What is the dividend yield of CIPLA?
0.93%: dividends of ₹13.00 per share with ex-dates in the last 12 months, divided by the latest price.
What return has CIPLA given?
1 year −6.7%, 3 years +16.2%, 5 years +53.9% (price only, dividends not included).
Which sector is CIPLA in?
NSE classifies Cipla Ltd. under Healthcare. Other Nifty 50 companies in it: APOLLOHOSP, DRREDDY, MAXHEALTH, SUNPHARMA.
Who owns CIPLA?
On 30 Sep 2026, promoters held 29.21% and the public 70.79%.
How can I buy CIPLA shares?
Through a SEBI-registered stockbroker with a demat and trading account. stockER is an information site only: it doesn't sell shares or recommend buying or selling any of them.